SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020.
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the p...
Read moreCNIC scientists have defined the unique ability if metoprolol to protect the heart during a heart attack
Read morePromega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug cand...
Read moreThe results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.
Read moreWe are happy to share our latest report from the work carried out in collaboration with GlaxoSmithKline and the Drug Discovery Unit of the University of Dundee. The paper published in RSC Medicinal Ch...
Read moreSOM Biotechhas been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 h...
Read moreNonalcoholic steatohepatitis (NASH) affects 2 to 5 percent of the world’s population. It is the most severe form of fatty liver disease, which can lead to cirrhosis, among other complications, and i...
Read more3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedi...
Read moreThe professor and researcher at the UdL and the IRBLleida Joan Fibla, the doctor from the HUAV Emergency Service Oriol Yuguero and the UdL researcher Marina Laplana lead the project, which will be car...
Read moreIBEC researchers led by ICREA Research Professor Núria Montserrat, together with international collaborators, have identified a drug capable of blocking the effects of the SARS-Co-V2 virus, the origi...
Read moreAn alternative to the use of antibiotics created by the group of Dr. Rafael Mañez, from the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital (HUB), has been sel...
Read more